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Abstract Optimizing designs using robust (global) opti-
mality criteria has been shown to be a more flexible
approach compared to using local optimality criteria.
Additionally, model based adaptive optimal design
(MBAOD) may be less sensitive to misspecification in the
prior information available at the design stage. In this
work, we investigate the influence of using a local (lnD) or
a robust (ELD) optimality criterion for a MBAOD of a
simulated dose optimization study, for rich and sparse
sampling schedules. A stopping criterion for accurate effect
prediction is constructed to determine the endpoint of the
MBAOD by minimizing the expected uncertainty in the
effect response of the typical individual. 50 iterations of the
MBAODs were run using the MBAOD R-package, with
the concentration from a one-compartment first-order
absorption pharmacokinetic model driving the population
effect response in a sigmoidal EMAX pharmacodynamics
model. The initial cohort consisted of eight individuals in
two groups and each additional cohort added two individ-
uals receiving a dose optimized as a discrete covariate. The
MBAOD designs using lnD and ELD optimality with
misspecified initial model parameters were compared by
evaluating the efficiency relative to an lnD-optimal design
based on the true parameter values. For the explored
example model, the MBAOD using ELD-optimal designs
converged quicker to the theoretically optimal lnD-optimal
design based on the true parameters for both sampling
schedules. Thus, using a robust optimality criterion in
MBAODs could reduce the number of adaptations required
and improve the practicality of adaptive trials using opti-
mal design.
Keywords Model based adaptive optimal design  Dose
optimization  Robust optimal design  ELD  API  Study
design
Introduction
When designing a future study, what is thought to be
known beforehand might not be a good representation of
the truth. Whether deciding upon sample size, sampling
schedule or which covariate to prioritize, the traditional
experimental design approaches are dependent on the prior
information and the resulting design will be based on an
expectation of reality. With the rising use of nonlinear
mixed-effects models (NLMEM) in drug development in
the past decades, new tools have become available to
predict what to expect in more intricate detail by study
simulation. As an extension of the NLMEM, model based
optimal experimental design (OD) has become a recog-
nized methodology for the design of pharmaceutical stud-
ies. In OD, the informativeness of a potential design is
summarized in the Fisher information matrix (FIM) [1]. By
finding the design which maximizes FIM, the expected
variance–covariance matrix can be minimized according to
the Cramer–Rao inequality [2, 3].
Several optimality criteria have been developed to allow
for numerical comparison of FIMs when optimizing the
designs. The most common criteria are D-optimality, in
which the determinant of the FIM is maximized to find the
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best design, and lnD-optimality where the natural loga-
rithm of the determinant of the FIM is maximized. D-op-
timality and lnD-optimality are considered local criteria
which assume that model parameters are known single
point values. There are however criteria for global (robust)
design in which only prior distributions of the parameters
are assumed to be known. Global design criteria have been
shown to be more flexible than local criteria and may be
less sensitive to parameter misspecification in the design
stage [1, 4–7]. One example of a global design criterion is
ELD-optimality where the expectation of the natural log-
arithm of the determinant of the FIM for the prior distri-
bution of parameters is maximized (the criterion is also
known as API optimality [8]). Regardless of the chosen
optimality criterion, a design optimized using the regular
model based OD methodology will be dependent on the
prior information regarding the model and parameters. If
the prior is not a good representation of the truth, the
design will be based on a misspecified guess of the model
and parameters, potentially resulting in a sub-optimal
design. Thus even when using OD for the design of a future
study, there is a risk of not finding a desired outcome due to
misspecified prior information in the design stage.
However, adaptive designs approaches for sequential
trials such as model based adaptive optimal design
(MBAOD) have been shown to be less sensitive to mis-
specified prior information in the design stage [9, 10].
Instead of preforming the optimal design for the entire
study population based on the information available prior
to the trial, as in a regular OD, the MBAOD approach
divides the study population into smaller cohorts. At the
initial cohort, the design is based on the prior information.
However, for the following cohorts, the prior information
regarding the parameters and model can be updated with
the information gained from the previous cohort. Thus, the
adaptive design approach will continuously improve the
parameter and model guess for the subsequent cohorts.
This iterative approach of guessing, learning, and
improving the design, may continue until an entire study
population has been enrolled. Additionally, the MBAOD
can be stopped before recruitment of all available subjects
using a stopping criterion for the MBAOD. The stopping
criterion, which can be based on, for example, a maximum
parameter variability or accuracy of the model prediction,
can then be evaluated at the end of each cohort to deter-
mine if the study should be stopped.
The aim of this work is to investigate any potential
advantage in using robust design criteria in MBAODs of a
simulated pharmacokinetic–pharmacodynamics (PKPD)
study when the dose of a hypothetical drug is optimized.
For the purpose of the study simulation, the prior
information regarding pharmacodynamics (PD) is assumed
to be misspecified, resulting in a 50% over estimated initial
guess of the PD fixed effect parameters. The pharmacoki-
netics (PK) of the PKPD model is assumed to be well
characterized with fixed parameter values to reduce the
complexity of the parameter estimation. No model mis-
specification is included. The stopping criteria for the
MBAOD assumes that the PD fixed effect curve will have a
95% confidence interval (CI) within 60–140% of the
population mean effect prediction, for all sampling points
and included doses.
For a rich and sparse sampling schedule, and using lnD
and ELD optimality criterion, the design efficiency of the
chosen doses for each cohort in the MBAODs is compared
relative to an lnD-optimal design based on the true
parameters. Additionally, the potential influence of the
optimality criterion on the number of individuals required
to reach the stopping criteria of the MBAOD, final
parameter relative estimation error and the overall dose
selection is evaluated.
Theoretical
With the vector of fixed effect parameters b ¼ b1; . . .; bj
 
and the vector of random inter-individual deviations from
the fixed effects gi ¼ ½gi;1; . . .; gi;k the ith individual’s
parameter vector hi is described by hi ¼ gðb; giÞ. The ith
individual’s response yi can be given by the response
function f and the residual error function h, describing the
random unexplained variability (RUV), as
yi ¼ f hi; nið Þ þ h hi; ni; eið Þ ð1Þ
where ni is the individual design vector containing design
variables such as sampling times and covariates and ei is the
residual error vector. For simplicity, with no covariance in the
random effects, gi and ei are sampled normal distributionswith
mean 0 and covariance matrix X ¼ diagðx21; . . .;x2kÞ andP ¼ diagðr21; . . .;r2mÞ respectively. The vector of random
effects can thus be constructed as k ¼ ½x21; . . .;x2k ; r21; . . .; r2m
giving the vector of population parameters H ¼ b; k½  ¼
b1; . . .; bj;x
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. The expected model
responseE yið Þ and varianceVðyiÞ oftenmust be approximated
since f hi; nið Þ may lack an exact solution due to non-linearity
with respect to the random effect parameters. Therefore, the
model in Eq. (1) is linearized, often using a first order Taylor
expansion, with respect to gi and ei to guarantee marginal
normally distributed observations. The fastest and simplest
approximation of the model is the first order approximation
(FO) where the model is linearized around the typical values
gi = 0 and ei = 0 [11].
If the expectation of response E yið Þ and variance VðyiÞ
are normally distributed, the subject specific fisher infor-











A EðyiÞ;VðyiÞð Þ ¼ 2  oE yið Þob
T
V yið Þ1oE yið Þob
þ tr oV yið Þ
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Furthermore, FIMi, can be reduced to its block-diagonal
form if the fixed effects are assumed to be independent on
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A EðyiÞ;VðyiÞð Þ ¼ 2  oE yið Þob
T
V yið Þ1 oE yið Þob
If the study consists of N independent groups with si
individuals per group, and all individuals in a group have
the same elementary design then the population FIM can be
constructed as the sum of FIMs for all groups as
FIM H; nð Þ ¼
XN
i¼1
si  FIMi H; nið Þ: ð4Þ
where n ¼ n1; . . .; ni½  contains all elementary designs.
The design criteria compared in this work are lnD-op-
timality and ELD-optimality which finds the design that
maximizes the block-diagonal FIM accordingly
nlnD ¼ arg max
n
ln FIMblockdiag H; nð Þ 	 
 ð5Þ
and
nELD ¼ arg max
n
EH ln FIM
blockdiag H; nð Þ 	 
  ð6Þ
where EH is the expectation over the prior distribution of
the parameters H. For a more comprehensive description
on the derivation of the FIM, for different linearizations,
and additional design criteria see [8, 11, 12].
Methods
In this work, the response model f was described by a
sigmoidal Emax PD model being driven by drug concen-
tration described by a one-compartment first order
absorption PK. The PK model was assumed to be known
and fixed with parameter values based on the warfarin PK
model used in [13, 14]. The RUV of the PD model was
given by a combined additive and proportional residual
error model. The ith individual’s effect response yi was
given by














Ci ti; hið Þ ¼ Dose  bKa







EMAXi ¼ bEmax  egEmax;i ð9Þ
EC50i ¼ bEC50  egEC50;i ðmg=LÞ ð10Þ
Cli ¼ bCL  egCL;i ðL=hÞ ð11Þ
Vi ¼ bV  egV;i ðLÞ ð12Þ
where ti is the individual vector of time points at which the
system response is evaluated.
Design setup
Using the response model described above, a MBAOD for
a dose optimization trial was run 50 times using the
MBAOD R-package [15] in four possible design scenar-
ios; lnD or ELD-optimality for a sparse sampling sched-
ule with three samples at tsparse = (0.5,3,60) h, and lnD or
ELD-optimality for a rich sampling schedule with eight
samples trich = (0.5, 2, 3, 6, 24, 36, 72, 120) h. The
sampling schedules were fixed and the same for all
individuals and groups. For the optimizations using ELD
optimality, a normal distribution was assumed for the
fixed effects parameters with mean bj and standard
deviation SDj. In the first cohort SDj was calculated from
a 10% coefficient of variation and for the subsequent
cohorts, SDj was updated from the parameter variance in
the COVb from the estimation using all previous cohorts.
The expectation of the FIM was based on 10 samples




In all MBAODs the initial parameter guess was a ?50%
misspecification of the true fixed-effect model parameters
(Table 1) and the dose was treated as a discrete covariate
with the allowed range of 0–500 mg in integer steps. The
initial design (before optimization) for the first cohort was
two groups dosed with 0 and 160 mg of the hypothetical
compound and four individuals per group. Subsequent
cohorts added one additional group with two individuals
receiving an optimized dose. A maximum of 50 cohorts
was allowed. At the start of each cohort, the dose was
optimized using the current, updated, parameter guesses
(and for ELD-optimization the parameter uncertainties).
Optimization was performed using the R-version of PopED
[8, 16]. Following the design optimization, individual data
was simulated using this design using the true parameter
values. For all cohorts, the parameters were then estimated
for all simulated data (including data from any previous
cohorts) using the FOCEI algorithm in NONMEM 7.3 [17]
via PsN version 4.5.16 [18]. After the estimation step the
MBAOD entered the stopping criterion evaluation (de-
scribed below) to determine whether a new cohort of
(simulated) patients should be included in the trial. If the
stopping criterion was not achieved, the MBAOD contin-
ued by updating the current guess of the parameters based
on the information from all the previous cohorts and
entered another cycle of design optimization, study simu-
lation and parameter estimation.
Stopping criterion
In the stopping criterion, 100,000 fixed effect parameter
vectors were generated with a multivariate student’s
t-distribution (rmvt) from the mvtnorm R-package:
simb ¼ rmvtðdf ; bb; SÞ ð13Þ
where simb is a matrix of 100,000 simulated parameter
vectors, bb is a vector of the estimated fixed effect param-
eters from NONMEM, df is the degrees of freedom and S is
the scale matrix. The degrees of freedom was dependent on
the cumulative number of included individuals nID and the
number of estimated parameters accordingly:





where nb^ and nk^ are the number of estimated fixed effect
and random effect parameters respectively. Given the
variance–covariance matrix for the fixed effects COVb^
from NONMEM and the degrees of freedom df, the scale
matrix S was constructed as
S ¼ COVb^ðdf  2Þ
df
ð15Þ
The parameters in simb were used by the model to simulate
100,000 population mean responses at the times specified
by the sampling schedule vector t, for all dose arms
included in the study. From the simulated responses, 95%
CIs of the predicted response at each sample time for all
doses was constructed. If all CIs fell within 60–140% of the
population mean response for all sampling times and doses,
the study was stopped.
Comparison of designs
The MBAODs using lnD-optimality and ELD-optimality
for rich and sparse sampling schedules were compared via
the total required number of simulated individuals to reach
Table 1 Parameter values of
the PKPD response model for
the true values used for
simulation and the misspecified
initial guess of the parameters
(in bold in the far right column)
Parameter Description True Guess
bCL (L/h) Clearance 0.15 FIX Same
bV (L) Volume of distribution 8 FIX Same
bKa (mg/h) Absorption rate 1 FIX Same
bBase (–) Baseline effect 1 1.5
bEMAX (–) Maximum effect 100 150
bEC50 (mg/L) 50% of maximum effective concentration 7 10.5
bc (–) Sigmoidicity Coefficient 2 3
x2CL (L/h) Between subject variability of CL 0.07 FIX Same
x2V (L) Between subject variability of V 0.02 FIX Same
x2EMAX (L/h) Between subject variability of EMAX 0.0625 Same
x2EC50 (L) Between subject variability of EC50 0.0625 Same
r2add (mg/L) Additive residual error component 0.001 FIX Same
r2prop (–) Proportional residual error component 0.015 Same
‘‘FIX’’ indicates that the parameters were not estimated, but rather assumed known in both design opti-
mization and parameter estimation
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the pre-determined stopping criteria and the relative esti-
mation error of the final parameter estimates. The relative
estimation error of the final estimate of parameter j in







where bbj is the estimate x of the true value bj of parameter
j.
Further, each design was compared to the theoretically
best design, generated by simulating an MBAOD using
lnD-optimality and while assuming the correct model
parameter values and with no parameter updating in the
MBAOD process. This comparison was done, first, by
computing the efficiency of each MBAOD design bn, based
on the initial parameter guess bH, relative to the theoreti-











where n is the optimal design based on the true parameters
in H and P is the total number of estimated parameters.
From the multiple MBAOD simulations, the median design
efficiency and a 95% non-parametric confidence interval
was constructed from the 2.5th and 97th percentiles of
design efficiency for each cohort. Second, the distribution
of selected doses across all iterations for all designs was
summarized in a histogram and compared to the the cor-
responding theoretically best design.
Results
With the initial parameter misspecification of ?50% on
all PD fixed effect parameters, the MBAODs using ELD-
optimality had efficiencies that stabilized more quickly to
values close to the theoretically optimal lnD-design based
on the true parameters, for both sparse and rich sampling
(Fig. 1). For the sparse sampling designs, the median
result of the MBAODs using ELD and lnD had high
efficiency even at the second cohort, but the variability in
efficiency between MBAOD iterations was much smaller
with the ELD designs compared to the lnD designs. After
the second cohort of patients the ELD and lnD designs
Fig. 1 The efficiency of the
MBAOD designs based on lnD
(Top) and ELD (Bottom)
optimality assuming 50%
misspecification in PD fixed-
effect parameters, relative to a
lnD-optimal design based on the
true parameter values, for the
sparse (Left) and rich (Right)
sampling schedules. The line
and the upper and lower bracket
limits represent the 50th, 2.5th
and 97.5th percentiles of the
achieved design efficiency after
each adaptive cohort from 50
MBAOD simulations
Fig. 2 Boxplots of the total sample size required to reach the
endpoint for 50 iterations of the model based adaptive optimal design




Fig. 3 Boxplots of relative
estimation error for the final
parameter estimates in 50
iterations of the model based
adaptive optimal design using
lnD-optimality and ELD
optimality for rich and sparse
sampling schedules
Fig. 4 Histogram of the dose
chosen (Grey) in all cohorts in
50 iterations of the model based
adaptive optimal design using
lnD-optimality(Top) and ELD
optimality (Bottom) for sparse
(left) and rich (right) sampling
schedules. The black outline
represents the dose selection by
the theoretically best lnD
optimal design based on the true
parameter values for the same




were very similar. For the rich sampling designs, the
relative efficiencies of the designs were also high at the
second cohort of patients. The efficiencies of the ELD
designs between MBAOD iterations were somewhat
higher than the lnD designs for the first four iterations,
but from the fifth iteration and forward the designs were
very similar.
The number of individuals required to reach the
stopping criteria of the MBAOD was similar between the
lnD and ELD-optimal designs (Fig. 2). The maximum
number of required cohorts and individuals was however
less for the MBAOD using ELD-optimality in the sparse
sampling schedule scenario (Figs. 1, 2). Additionally,
there was little difference in the relative estimation error
between the optimality criteria (Fig. 3). The ELD resul-
ted in a more even distribution of chosen doses across all
50 iterations of the MBAOD and included the doses
from the lnD-optimal design based on the true parame-
ters more often than the MBAODs using lnD-optimality
(Fig. 4).
Discussion and conclusion
In this work, the effects of lnD and ELD optimality were
compared for model based optimal designs of simulated
dose optimization PKPD studies with rich and sparse
sampling. A stopping criterion for the MBAOD was con-
structed based on the accuracy of the effect prediction. The
designs from the two optimality criteria were compared in
terms of required sample size, final parameters, dose
selection and efficiency relative to the true lnD-optimal
design.
There were differences in the MBAODs using lnD- and
ELD-design calculations (Fig. 4) as well as in the speed at
which the lnD or ELD design approached the efficiency of
a lnD design calculated without model parameter mis-
specification. With the ELD designs achieving high effi-
ciency after just 2–3 cohorts of patients, compared to 3–5
cohorts needed for the lnD designs. Additionally, design
efficiencies in the second cohort were more variable when
using lnD-optimality than ELD-optimality, indicating
designs that are more sensitive to parameter estimates from
the initial cohort of patients and less robust to parameter
misspecification.
These differences were not noticeable in the number of
individuals needed to achieve the MBAOD stopping cri-
teria (Fig. 2), or in parameter bias (Fig. 3) for the 50
MBAOD iterations in this example. This apparent insen-
sitivity to the lnD or ELD design criteria in the final
parameter estimates and number of individuals in the study
could clearly be influenced by many factors. First of all,
only one set of true and misspecified parameters was
investigated. The design setup (number of individuals per
cohort, number of cohorts) and lowering the precision
criteria (from 60 to 140% of the mean prediction to
80–120% for example) could also influence results. In
addition, in this particular example, optimizing both dose
and sample times could have shown more differences
between the robust and local design criteria since it would
require the optimizations to find more optimal design
support points. Further, for the optimization using the ELD
approach, only 10 samples were taken from the prior dis-
tribution due to long run times, a large variance of the ELD
criterion may have destabilized the design. By increasing
the number of samples, the ELD approach could potentially
have been more robust.
However, in this example with these experimental
settings we see that the adaptive properties of a MBAOD
allow for local designs to be as robust as global optimality
criteria given that the local designs are allowed to adapt a
sufficient number of times. The MBAODs using ELD-
optimality did however converge quicker towards the
‘‘true’’ design, resulting in a maximum number of required
cohorts which was lower compared to the lnD–MBAOD.
Additionally, the doses according to the theoretically true
lnD-optimal design was included in the MBAOD more
often by the robust design (Fig. 4). The main disadvantage
of using ELD optimality in these examples was increased
run-times for design optimization. However, compared to
the time to execute the study on each adaptive cohort in a
real practical setting, these additional run-times would be
negligible. With the ELD MBAODs achieving more effi-
cient and robust designs earlier in the adaptive process,
this allows the MBAOD to approach a more practical
2-step or 3-step sequential design [19, 20]. Thus using a
robust optimality criterion in MBAOD could be more
practical for performing adaptive trials using optimal
design.
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